INTRODUCTION {#s1}
============

Gastric cancer (GC), one of the most common malignancies, is the second most cause of mortality worldwide \[[@R1]\]. Although rapid improvement of surgery and adjuvant treatment in past decade, the prognosis of GC patients remained unsatisfactory owing to recurrence or metastasis after curative resection \[[@R2]\]. Therefore, promising prognostic biomarker which predicted its progression and survival would be helpful for management and treatment in these patients.

It has been well known that inflammation and nutrition are closely associated with progression and survival of GC \[[@R3]--[@R5]\]. Anti-inflammatory treatment and nutritional care could prevent cancer progression and improve prognosis of the patients \[[@R5]--[@R7]\]. Seo *et al.* reported that preoperative adequate albumin (Alb) and energy intake could improve therapeutic effect of the patients \[[@R5]\]. Kim *et al.* demonstrated that long-term low-dose aspirin intake could reduce susceptibility to GC \[[@R7]\]. Circulating nutritional and inflammatory mediators such as fibrinogen(Fib), Alb and pre-albumin(pAlb) are usually aberrant in these patients. Emerging evidences indicated that high level of plasma Fib were significantly associated with poor clinical outcome of GC patients \[[@R8]--[@R10]\], and preoperative low serum pAlb level and hypoalbuminemia were considered to be predictors for shorter overall survival (OS) in GC patients \[[@R11], [@R12]\]. A recent study reported that circulating albumin to gamma-glutamyltransferase ratio could apparently improve predictive accuracy for OS in resected intrahepatic cholangiocarcinoma patients in comparison with TNM staging systems alone \[[@R13]\]. Thus, we speculated that circulating Alb/Fib ratio (AFR) and Fib/pAlb ratio (FPR), which reflected status of inflammation and nutrition, would be novel inflammatory biomarkers of prognostic prediction for postoperative stage II and III GC patients.

We firstly compared the clinical efficacy of preoperative circulating Fib, Alb, and pAlb, either alone or pooled, for 3 years' clinical outcome in stage II and III GC patients. Our findings revealed that FPR could independently predict postoperative OS with superior accuracy compared with the other prognostic indicators and select the patients who could benefit from adjuvant chemotherapy. Additionally, a reliable prognostic nomogram based on clinical parameters and FPR could improve its predictive value of OS in the patients.

RESULTS {#s2}
=======

Clinical characteristics of GC patients {#s2_1}
---------------------------------------

Enrolled 360 stage II and III GC patients included 261 male (72.5%) and 99 (27.5%) female and median age was 58 years (ranged from 21 to 86). During 3 years' following up, 120 (33.3%) patients were confirmed dead and 240 (66.7%) were alive. The postoperative histology results revealed that the majority of the patients were deep invasion (T3/T4) and lymph node metastasis (76.1% and 62.8%, respectively). There were 88 (24.4%) patients with large tumor size (\>5cm). Almost half of them had poor differentiated and received adjuvant chemotherapy (55.8% and 69.3%, respectively). The median values of CEA, CA199, Fib, Alb, pAlb, AFR and FPR were 5.59 (0.1-100) ng/ml, 51.81 (0.9-700) U/ml, 3.31 (0.93-6.27) mg/dl, 38.79 (26.21-49.57) g/l, 214.15 (67.3-437.9) mg/l, 12.96 (5.76-43.26), 17.97 (3.03-83.47), respectively. Other details of features are summarized in Table [1](#T1){ref-type="table"}.

###### Clinical and pathological characteristics in 360 gastric cancer patients

  Variables               Categories   Total patients(n=360)
  ----------------------- ------------ -----------------------
                                       No. of patients (%)
  Gender                  Male         261(72.5)
                          Female       99(27.5)
  Age                     year         58.24±11.22
  Tobacco                 Yes          120(33.3)
                          No           240(66.7)
  Alcohol                 Yes          82(22.8)
                          No           278(77.2)
  Hypertension            Yes          44(12.2)
                          No           316(87.8)
  Diabetes                Yes          17(4.7)
                          No           343(95.3)
  Adjuvant Chemotherapy   Yes          249(69.2)
                          No           111(30.8)
  Differentiation         well         159(44.2)
                          poor         201(55.8)
  Tumor stage             II           123(34.2)
                          III          237(65.8)
  Depth of invasion       T1-T2        86(23.9)
                          T3-T4        274(76.1)
  Lymph node              N0           134(37.2)
                          N1-N3        226(62.8)
  Tumor size              ≤5cm         272(75.6)
                          \>5cm        88(24.4)
  Fib                     mg/dl        3.31(0.93-6.27)
  Alb                     g/l          38.79(26.21-49.57)
  pAlb                    mg/l         214.15(67.3-437.9)
  FPR                                  17.97(3.03-83.47)
  AFR                                  12.96(5.76-43.26)
  CEA                     ≤5 ng/ml     309(85.8)
                          \>5 ng/ml    51(14.2)
  CA199                   ≤37 U/ml     303(84.2)
                          \>37 U/ml    55(15.3)
                          NA           2(0.5%)
  3 years' OS             month        36

Abbreviation: NA: not available; Fib: fibrinogen; Alb: albumin; pAlb: pre-Albumin; AFR: albumin/fibrinogen ratio; FPR: fibrinogen/pre-Albumin ratio (FPR); CEA: carcinoembryonic antigen; FAS: FPR and Alb Score; mFAS: modified FPR and Alb Score; OS: overall survival;

The optimal thresholds for Fib, Alb, pAlb, AFR and FPR {#s2_2}
------------------------------------------------------

The optimal cut-points using X-tile program for preoperative circulating Fib, Alb, pAlb, AFR and FPR were 3.3 mg/dl, 37 g/l, 195.9 mg/l, 8.9 and 12.1, respectively (Figure [1](#F1){ref-type="fig"} and [Supplementary Figure 1](#SD1){ref-type="supplementary-material"}). According to the optimal cut-points, enrolled patients were divided into low- and high- groups. The details are shown in Table [2](#T2){ref-type="table"}.

![The optimal cut-off of preoperative circulating FPR in 360 surgically resected GC patients using X-tile software\
The optimal cut-point of FPR ratio in the panels is shown on the histogram and corresponding populations are displayed on the Kaplan--Meier curve.](oncotarget-08-75195-g001){#F1}

###### Correlation of preoperative circulating Fib, Alb, pAlb, AFR and FPR with clinicopathological characteristics in 360 GC patients

  Characteristics              Patients grouped by   *P*^*\**^   Patients grouped by   *P*^*\**^   Patients grouped by   *P*^*\**^   Patients grouped by   *P*^*\**^   Patients grouped by   *P*^*\**^                               
  ------------------- -------- --------------------- ----------- --------------------- ----------- --------------------- ----------- --------------------- ----------- --------------------- ----------- ----- --------- ----- ----- ---------
  Gender              Male     177                   84          0.732                 204         57                    0.062       122                   139         0.463                 179         82    0.253     154   107   0.049
                      Female   69                    30                                86          13                                42                    57                                74          25              47    52    
  Age(years)          ≤60      120                   86          \<0.001               182         24                    0.015       70                    136         \<0.001               162         44    \<0.001   127   79    0.010
                      \>60     126                   28                                108         46                                94                    60                                91          63              74    80    
  Tobacco             Yes      83                    37          0.810                 90          30                    0.060       63                    57          0.061                 78          42    0.121     64    56    0.499
                      No       163                   77                                200         40                                101                   139                               175         65              137   103   
  Alcohol             Yes      55                    27          0.780                 62          20                    0.198       41                    41          0.358                 52          30    0.122     46    36    0.956
                      No       191                   87                                228         50                                123                   155                               201         77              155   123   
  Hypertension        Yes      29                    15          0.712                 35          9                     0.857       24                    20          0.201                 29          15    0.499     26    18    0.642
                      No       217                   99                                255         61                                140                   176                               224         92              175   141   
  Diabetes            Yes      13                    4           0.597                 9           8                     0.003       12                    5           0.034                 12          5     0.977     6     11    0.081
                      No       233                   110                               281         62                                152                   191                               241         102             195   148   
  Chemotherapy        Yes      164                   85          0.131                 206         43                    0.118       109                   140         0.310                 185         64    0.012     143   106   0.361
                      No       82                    29                                84          27                                55                    56                                68          43              58    53    
  Differentiation     well     111                   48          0.592                 125         34                    0.408       71                    88          0.760                 106         53    0.182     90    69    0.793
                      poor     135                   66                                165         36                                93                    108                               147         54              111   90    
  Tumor stage         II       67                    56          \<0.001               110         13                    0.002       40                    83          \<0.001               100         23    0.001     78    55    0.048
                      III      179                   58                                180         57                                124                   113                               153         84              123   54    
  Depth of invasion   T1-T2    45                    41          \<0.001               78          8                     0.006       27                    59          0.003                 71          15    0.004     56    30    0.047
                      T3-T4    201                   73                                212         62                                137                   137                               182         92              145   129   
  Lymph node          N0       83                    51          0.045                 118         16                    0.006       52                    82          0.048                 105         29    0.010     81    53    0.175
                      N1-N3    163                   63                                172         54                                112                   114                               148         78              120   106   
  Tumor size(cm)      ≤5       175                   97          0.004                 232         40                    \<0.001     112                   160         0.003                 203         69    0.001     169   103   \<0.001
                      \>5      71                    17                                58          30                                52                    36                                50          38              32    56    
  CEA(ng/ml)          ≤5       203                   106         0.008                 255         54                    0.020       136                   173         0.143                 218         91    0.781     178   131   0.096
                      \>5      43                    8                                 35          16                                28                    23                                35          16              23    28    
  CA199(U/ml)         ≤37      201                   102         0.045                 244         59                    0.823       134                   169         0.244                 214         89    0.818     175   129   0.163
                      \>37     44                    11                                45          10                                29                    26                                38          17              26    29    
  OS                  alive    143                   97          \<0.001               208         32                    \<0.001     91                    149         \<0.001               185         55    \<0.001   157   83    \<0.001
                      dead     103                   17                                38          38                                73                    47                                68          52              44    76    

The correlation of Fib, Alb, pAlb, AFR and FPR with the clinical parameters {#s2_3}
---------------------------------------------------------------------------

In order to investigate associations of these factors with tumor stage, 44 stage I GC patients were enrolled in our study. We compared the high groups and low groups for these indicators and increased Fib, FPR and deceased Alb, pAlb and AFR were positively correlated with age (more than 60 years), tumor size (larger than 5cm), tumor stage (III), depth of invasion depth (T3-T4), lymph node metastasis (N1-N3) and poor OS (all *P*\<0.001) (Table [2](#T2){ref-type="table"} and Figure [2](#F2){ref-type="fig"}). Compared with 30 preoperative patients, higher FPR were in the patients with recurrent GC (*P*=0.001) (Figure [2F](#F2){ref-type="fig"}). Besides, no significant association was observed among alcohol, tobacco, hypertension, diabetes, tumor differentiation and adjuvant chemotherapy in two groups.

![The relationship between tumor stage and Fib, pAlb, Alb, AFR, FPR in 360patients with GC and comparison of FPR in preoperative and recurrent 30 GC patients\
**(A)** Fib; **(B)** pAlb; **(C)** Alb; **(D)** AFR; **(E)** FPR; **(F)** comparison of FPR in preoperative and recurrent patients. \**P*\<0.05, \*\**P*\<0.01, \*\*\**P*\<0.001, ns: not significant.](oncotarget-08-75195-g002){#F2}

The association between baseline characteristics and clinical prognosis {#s2_4}
-----------------------------------------------------------------------

Kaplan--Meier survival curve and log-rank test were performed to investigate the association between pathological data and postoperative 3-year survival time. The 3 years' OS curves according to Fib, pAlb, AFR and FPR were shown in [Supplementary Figure 2](#SD1){ref-type="supplementary-material"}. Both Kaplan--Meier curves and univariate analysis showed that sex, tobacco, alcohol, hypertension and diabetes were not significantly associated with OS (*P*\>0.05), while patients with older age (HR=1.541, *P*=0.018), worse differentiation (HR=1.890, *P*=0.001), larger tumor size (HR=2.580, *P*\<0.001), deeper invasion (HR=6.238, *P*\<0.001), higher tumor stage (HR=5.872, *P*\<0.001), CEA (HR=2.250, *P*\<0.001), CA199 (HR=1.932, *P*=0.003), Fib (HR=2.142, *P*\<0.001) and FPR (HR=3.373, *P*\<0.001), lower Alb (HR=2.140, *P*\<0.001), pAlb (HR=2.672, *P*\<0.001), AFR (HR=2.343, *P*\<0.001), worse tumor differentiation (HR=1.890, *P*=0.001) and more lymph node metastases (HR=3.874, *P*\<0.001) were significant prognostic factors for worse OS (Table [3](#T3){ref-type="table"}). Multivariate analysis showed that not only worse differentiation (adjusted HR=1.774, *P*=0.005), larger tumor size (adjusted HR=1.930, *P*=0.001) and more lymph node metastases (adjusted HR=2.201, *P*=0.009), but also lower Alb (adjusted HR=1.614, *P*=0.014), pAlb (adjusted HR=2.111, *P*\<0.001), AFR (adjusted HR=1.540, *P*=0.044) and higher CEA (adjusted HR=1.739, *P*=0.013), FPR (adjusted HR=2.325, *P*=0.002) were identified as independent prognostic factors for shorter OS, but age, Fib and CA199 were not (*P*\>0.05) (Table [3](#T3){ref-type="table"}).

###### Univariate and multivariate analyses of prognostic factors for 3 years' OS by Cox regression model

  Variables                   Overall survival                                                         
  --------------------------- ------------------ --------------- ------------- ------- --------------- -------------
  Sex (male)                  11.051             (0.701-1.574)   0.811         \-                      \-
  Age (\>60 years)            1.541              (1.077-2.205)   **0.018**     1.328   (0.905-1.948)   0.147
  Tobacco (yes)               1.020              (0.698-1.490)   0.920         \-                      **-**
  Alcohol (yes)               1.167              (0.772-1.765)   0.463         \-                      \-
  Hypertension (yes)          1.345              (0.815-2.220)   0.247         \-                      \-
  Diabetes (yes)              1.483              (0.724-3.309)   0.281         \-                      \-
  Chemotherapy (no)           1.493              (1.032-2.161)   **0.034**     1.682   (1.136-2.488)   **0.009**
  Differentiation (poor)      1.890              (1.289-2.770)   **0.001**     1.774   (1.193-2.639)   **0.005**
  Tumor stage (III)           5.872              (3.233-10.67)   **\<0.001**   5.006   (2.712-9.241)   **\<0.001**
  Depth of invasion (T3-T4)   6.238              (2.906-13.39)   **\<0.001**   2.293   (0.917-5.738)   0.076
  lymph node (N1-N3)          3.874              (2.372-6.328)   **\<0.001**   2.088   (1.202-3.626)   **0.009**
  Tumor size(\>5cm)           2.580              (1.790-3.720)   **\<0.001**   1.930   (1.326-2.808)   **0.001**
  CEA (\>5 ng/ml)             2.250              (1.465-3.456)   **\<0.001**   1.739   (1.123-2.694)   **0.013**
  CA199 (\>37U/ml)            1.932              (1.258-2.968)   **0.003**     1.119   (0.686-1.824)   0.653
  Fib (\>3.0 mg/dl)           2.142              (1.484-3.091)   **\<0.001**   1.463   (0.996-2.149)   0.052
  Alb (≤36.4 g/l)             2.140              (1.490-3.072)   **\<0.001**   1.614   (1.103-2.361)   **0.014**
  pAlb (≤194.1 mg/l)          2.672              (1.842-3.875)   **\<0.001**   2.111   (1.437-3.100)   **\<0.001**
  AFR (≤8.9)                  2.343              (1.594-3.445)   **\<0.001**   1.540   (1.013-2.343)   **0.044**
  FPR (\>12.1)                3.373              (2.018-5.636)   **\<0.001**   2.325   (1.372-3.940)   **0.002**

Abbreviation: HR: hazard ratio; CI: confidence interval; Fib: fibrinogen; Alb: albumin; pAlb: pre-Albumin; AFR: albumin/fibrinogen ratio; FPR: fibrinogen/pre-Albumin ratio (FPR); CEA: carcinoembryonic antigen; HR (95%) was adjusted by sex, age, alcohol, tobacco, hypertension, diabetes, chemotherapy, tumor size, tumor grade, tumor stage, CEA and CA199.

Time-dependent ROC analysis {#s2_5}
---------------------------

To further evaluate the prognostic value of inflammation-based prognostic factors, time-dependent ROC analysis was performed. The result of time-dependent ROC analysis presented that the lower area under the receiver operating characteristic curve (AUC) for FPR in the early period (\<6 months) and the higher AUC therefore (\>6 months) among these prognostic indicators including Fib, Alb, pAlb, AFR, CEA and CA199 (Figure [3](#F3){ref-type="fig"}).

![Time-dependent ROC analysis of preoperative circulating Fib, Alb, pAlb, AFR, FPR, CA199 and CEA for clinical outcome of 360 GC patients](oncotarget-08-75195-g003){#F3}

FPR and clinical adjuvant chemotherapy {#s2_6}
--------------------------------------

We compared the prognosis of stage II and III GC patients receiving or not adjuvant chemotherapy in the subgroups stratified by FPR. Survivals of stage II and III GC patients were significantly longer in low FPR subgroup than them in high FPR subgroup (*P*=0.007 and *P*=0.002, respectively). Low level of FPR (adjusted HR=5.851, 95%CI=2.147-15.949) were significantly associated with reduced survival in the III stage patients without chemotherapy comparing to the patients undergoing chemotherapy. However, no difference of survival was examined in stage II subgroups stratified by FPR and high FRP of stage III subgroup receiving or not the treatment of adjuvant chemotherapy (Table [4](#T4){ref-type="table"} and Figure [4](#F4){ref-type="fig"}).

###### Univariate and multivariate analyses of high/low FPR for chemotherapy by Cox regression model

  Variables     Chemotherapy   Univariate analysis   Multivariate analysis                                  
  ------------- -------------- --------------------- ----------------------- ------- ------- -------------- -------
  FPR(\>12.1)   yes            1                                                     \-                     
                no             1.205                 0.806-1.803             0.363   \-                     
  FPR(≤12.1)    yes            1                                                     1                      
                no             2.990                 1.153-7.754             0.024   5.851   2.147-15.949   0.001

Abbreviation: HR: hazard ratio; CI: confidence interval; FPR: fibrinogen/pre-Albumin ratio; HR (95%) was adjusted by sex, age, alcohol, tobacco, hypertension, diabetes, tumor size, tumor grade, tumor stage, CEA and CA199.

![Kaplan--Meier curves analysis in each subgroup\
**(A)** stage II patient; **(B)** stage III patient; **(C)** high FPR subgroup; **(D)** low FPR subgroup; **(E)** FPR-high stage II subgroup; **(F)** FPR-low stage II subgroup; **(G)** FPR-high stage III subgroup; **(H)** FPR-low stage III subgroup.](oncotarget-08-75195-g004){#F4}

Prognostic nomogram for 3-year overall survival {#s2_7}
-----------------------------------------------

To predict the survival of stage II and III GC patients underwent surgical resection, prognostic nomograms were established using all the significantly independent indicators for OS (Figure [5A](#F5){ref-type="fig"}). The nomogram with FPR (c-index: 0.756) was more accurate than that without FPR (c-index: 0.748) in prediction of 3-year OS after initial surgery (Figure [5B](#F5){ref-type="fig"}).

###### Postoperative nomogram estimated by clinical characteristics and FPR for 3-years' OS in 360 GC patients

**(A)** without FPR; **(B)** with FPR.

![](oncotarget-08-75195-g005a)

![](oncotarget-08-75195-g005b)

DISCUSSION {#s3}
==========

Most of the GC patients are diagnosed in an advanced stage and the survival rates of them are relatively low, therefore, promising prognostic biomarkers that enable to identify the patients who could obviously benefit from chemotherapy and predict survival of them are crucial \[[@R14], [@R15]\]. In this study, we found that evaluated FPR was significantly associated with T3-4 invasion, node metastasis and larger tumor size and was superior to other biomarkers to independently predict poor survival both within stage II-III, II and III subgroups; moreover, clinical outcome of III stage patients with low FPR appeared to obviously benefit from adjuvant chemotherapy in comparison with high FPR stage III patients, and the biomarker could improve the predicted efficacy of nomogram for stage II-III GC.

To date, some researchers have reported that high level of Fib, low level of Alb and pAlb were recognized as important prognostic factors influencing cancer progression \[[@R10], [@R11], [@R16]\], which were consistent with our findings. Due to few patients died from the disease within 6 months after surgical resection, low AUC of FPR was observed in the early period, and the AUC was gradually increased and higher than the other biomarkers, indicating that FPR was superior to these biomarkers to apparently improve predictive efficacy of prognosis within II-III stage GC patients. In addition, it could precisely classify stage III GC patients who appeared to benefit from adjuvant chemotherapy obviously. The following causes might be accounted for our findings. Firstly, it had been shown that Fib acts as a bridging molecule between GC cells and surrounding microenvironment. Adams *et al.* demonstrated that it as a ligand for integrin and intercellular adhesion molecule presented on malignant cell surface to mediate coagulation, inflammation and immunity \[[@R17]\]. Secondly, Fib enhanced b3-integrin-mediated vascular endothelial adhesion of platelets to tumor cells, and platelets in turn promoted more Fib to aggregate around tumor cells by forming thrombin. They facilitated each other to protect tumor cells escaping from cytotoxicity of nature killer cells \[[@R18]\]. Palumbo *et al.* reported that lymphatic metastasis, but not primary tumor growth or angiogenesis, was diminished in fibrinogen-deficient mice, suggesting that Fib was a critical determinant of the metastatic potential by impeding elimination of tumor cell by natural killer cell \[[@R19], [@R20]\]. Thirdly, serum Alb was one of the most widely used markers for reflecting nutritional status and hypoproteinmia was reported as a crucial parameter of malnutrition and directly influenced prognosis of GC; low levels of Alb and pAlb levels have an impact on determinant of immune responses and malnutrition, which could impair immune system defending against GC \[[@R21], [@R22]\].

This study, to best of our knowledge, is the first to investigate prognostic role of AFR and FPR in GC. Certain advantages and limitations should address to explain our results. To some extent, hypoalbuminemia has been considered to be an inflammatory indicator in GC, rather than only a factor indicates malnutrition \[[@R4]\]. Therefore, single clinical blood marker is limited and unstable to predict prognosis of GC. Our results did firstly find that FPR is a superior prognostic indicator compared to Fib, Alb, or pAlb alone, for they reflected not only inflammation but also nutritional status of GC patients. Besides, circulating Fib to pAlb ratio will expand prognostic range to avoid a single indicator causing false negative or positive results. Finally, we figured out the visual nomogram based on FPR, which could predict prognosis in postoperative stage II and III GC patients within 3 years more accurately. Therefore, preoperative calculation of FPR may help to predict 3 years' OS in surgical GC patients. However, we acknowledge some potential limitations in our study. Since the results of our study may be affected by a short follow-up period, single-institution design and a small sample size retrospective study, larger patients with GC are required to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

Patients {#s4_1}
--------

Three hundred and sixty newly diagnosed stage II and III GC patients were included in this retrospective study and all of them underwent surgical resection from June 2011 to December 2013 at the Second Affiliated Hospital of Nanchang University. The diagnostic criteria for GC were according to the seventh edition of tumor-nodes-metastasis (TNM) staging system \[[@R23]\]. In the contrary, patients were excluded as follows: 1) all patients had infection or inflammation-related diseases for nearly one month, autoimmune diseases and blood diseases; 2) patients who received preoperative anti-inflammatory or anticancer therapy; 3) patients with abnormal liver function, mixed cancers and distant metastasis; 4) absent data regarding preoperative prognostic biomarkers. The study was approved by the Ethical Committee of the Second Affiliated Hospital of Nanchang University.

Data collection and laboratory detection {#s4_2}
----------------------------------------

Through patients' medical record and pathological report, we gathered data including age, sex, personal history and postoperative clinical and pathological characteristics. All peripheral blood samples were collected at 7:30 to 9:30 am within three days before surgical operation. Plasma and serum samples were centrifuged at 3000g for 5 min. Plasma Fib concentration were detected using Clauss method by SYSMEX CA-7000 machine (Sysmex, Tokyo, Japan), its inter- and intra-batch coefficient of variation (CV) of the kit were 4.41% and 3.66%, respectively. Bromocresol green, immune turbidimetric and electrochemiluminescence methods were used to detect serum Alb, pAlb, CA199 and CEA using OLYMPUS AU5400 machine(Beckman Coulter, Tokyo, Japan) and COBAS e411 (Roche, Basel, Switzerland), respectively. The inter- and intra-batch CVs of the kits were 3.17% and 1.83%, 3.09% and 2.76%, 3.32% and 3.25%, 3.48% and 3.26%, respectively. In each batch, blinded quality controlled samples were included, and all the markers were measured triplicate in all plasma samples.

Follow-up {#s4_3}
---------

After surgery, all stage II and III GC patients were followed up regularly until December 31^th^ 2016 (every 6 months up to 3th year by telephone). For drop-out patients, the date was obtained by outpatient medical records. Overall survival (OS) was measured from the date of operation to death from any causes or last following-up.

Statistical analysis {#s4_4}
--------------------

The optimal cut-off levels of prognostic factors were determined by X-tile software. Chi-square test and Mann--Whitney *U* or Kruskal--Wallis test were used to analyze categorical variables and continuous variables with non-normal distributions, respectively. Kaplan--Meier survival curve was applied for survival analysis and the differences in survival rate were performed by the log-rank test. Hazards ratio (HR) for death was estimated with a Cox proportional hazards model. Prognostic nomogram, Harrell's concordance index (c-index) and Time-dependent ROC were analyzed by the rms and survivalROC packages, respectively. Statistical analyses were carried out using SPSS 19.0 software (IBM Corp, Armonk, NY, USA) and R 3.0.3 software (Institute for Statistics and Mathematics, Vienna, Austria). *P*\<0.05 was indicated statistically difference.

CONCLUSIONS {#s5}
===========

It is worth emphasizing that preoperative FPR is more compelling in predicting three years' OS in surgical stage II and III GC than Fib or pAlb alone and adjuvant chemotherapy might be more beneficial to FPR-low stage III GC patients. Due to survival heterogeneity of GC patients, larger cohort prospective studies, especially prospective multicenter clinical trials, are warranted to further validate the results.
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